User profiles for Quentin M Anstee
 | Quentin M. AnsteeProfessor of Experimental Hepatology, Newcastle University, UK Verified email at newcastle.ac.uk Cited by 47668 |
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
NAFLD is one of the most important causes of liver disease worldwide and will probably
emerge as the leading cause of end-stage liver disease in the coming decades, with the …
emerge as the leading cause of end-stage liver disease in the coming decades, with the …
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
The exclusion of other chronic liver diseases including “excess” alcohol intake has until now
been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver …
been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver …
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
…, M Arrese, P Bedossa, PN Newsome, QM Anstee… - Gastroenterology, 2020 - Elsevier
Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population,
and has no approved drug therapy. Although pharmacotherapies are in development, …
and has no approved drug therapy. Although pharmacotherapies are in development, …
[HTML][HTML] NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1 , 2 , 3 , 4 – 5 . Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been …
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been …
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
NAFLD is a spectrum of progressive liver disease that encompasses simple steatosis, NASH,
fibrosis and, ultimately, cirrhosis. NAFLD is recognized as the hepatic component of the …
fibrosis and, ultimately, cirrhosis. NAFLD is recognized as the hepatic component of the …
[HTML][HTML] Advancing the global public health agenda for NAFLD: a consensus statement
Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects
approximately one-quarter of the global adult population, causing a substantial burden of ill …
approximately one-quarter of the global adult population, causing a substantial burden of ill …
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease
that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown …
that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown …
[HTML][HTML] Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030
C Estes, QM Anstee, MT Arias-Loste, H Bantel… - Journal of …, 2018 - Elsevier
Background & Aims Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis
(NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. …
(NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. …
[HTML][HTML] A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH
…, P Bedossa, V Ratziu, QM Anstee… - … England Journal of …, 2021 - Mass Medical Soc
Background Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need.
Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …
Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …
[HTML][HTML] Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis …
…, M Abdelmalek, S Caldwell, J Drenth, QM Anstee… - Gastroenterology, 2016 - Elsevier
Background & Aims Elafibranor is an agonist of the peroxisome proliferator−activated
receptor-α and peroxisome proliferator−activated receptor-δ. Elafibranor improves insulin …
receptor-α and peroxisome proliferator−activated receptor-δ. Elafibranor improves insulin …